Rituximab in paediatric onset multiple sclerosis: a case series

The Swedish MS registry - clinical support tool and scientific resource

(2015) J. Hillert et al.   ACTA NEUROLOGICA SCANDINAVICA

JC virus antibody status in a pediatric multiple sclerosis cohort: Prevalence, conversion rate and influence on disease severity

(2014) Peter Huppke et al.   Multiple Sclerosis Journal

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease

(2014) R. C. Dale et al.   NEUROLOGY

Rituximab Use in Pediatric Central Demyelinating Disease

(2014) Shannon J. Beres et al.   PEDIATRIC NEUROLOGY

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases

(2013) A Ghezzi et al.   Multiple Sclerosis Journal

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

(2013) Barbara Kornek et al.   JAMA Neurology

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Daclizumab Use in Patients With Pediatric Multiple Sclerosis

(2012) Mark P. Gorman   ARCHIVES OF NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis

(2011) A Scott Nielsen et al.   Multiple Sclerosis Journal

Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis

(2011) T Chitnis et al.   Multiple Sclerosis Journal

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis

(2009) Mark P. Gorman et al.   ARCHIVES OF NEUROLOGY

‘Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis’

(2009) Michael Karenfort et al.   DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE